Current Neuro-Oncology

Volume 27 Number 2
20 January 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 2, 20 January

Ohba S, Teranishi T, Matsumura K, Kumon M, Kojima D, Fujiwara E, Nakao K, Kuwahara K, Murayama K, Pareira ES, Yamada S, Joko M, Nakae S, Muto J, Nishiyama Y, Adachi K, Sasaki H, Abe M, Hasegawa M, Hirose Y.
Factors involved in maintaining Karnofsky Performance Status (≥ 50%) in glioblastoma, IDH-wildtype patients treated with temozolomide and radiotherapy.
Sci Rep. 2025 Jan 11;15(1):1750. doi: 10.1038/s41598-025-85339-x. PMID: 39799218. Observational study. ˍ

Xing H, Liu D, Li J, Ge Y, Guo X, Chen W, Zhao D, Shi Y, Li Y, Wang Y, Wang Y, Xia Y, Wu J, Liang T, Wang H, Liu Q, Jin S, Qu T, Guo S, Li H, Yang T, Zhang K, Wang Y, Ma W.
TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study.
Cancer Med. 2025 Jan 13;14(2):e70533. doi: 10.1002/cam4.70533. PMID: 39804195. Observational study. ˍ

Yuan H, Cheng J, Xia J, Yang Z, Xu L.
Identification of critical biomarkers and immune landscape patterns in glioma based on multi-database.
Discov Oncol. 2025 Jan 13;16(1):35. doi: 10.1007/s12672-024-01653-2. PMID: 39800804. Observational study. ˍ

Ali E, Ahmed MA, Shawki MA, El Arab LRE, Khalifa MK, Swellam M.
Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.
Sci Rep. 2025 Jan 14;15(1):1933. doi: 10.1038/s41598-024-83800-x. PMID: 39809835. Observational study. ˍ

Angoumis K, Padilla CS, Kouwenhoven MCM, Bijlsma RM, Kaal SEJ, Tromp JM, Bos MEMM, van der Hulle T, Broen MPG, Nuver J, van der Graaf WTA, Pauge S, Husson O.
Adverse health outcomes and health-related quality of life (HRQoL) among long-term adolescent and young adult (AYA) brain tumour survivors: results from the population-based SURVAYA study.
Support Care Cancer. 2025 Jan 14;33(2):95. doi: 10.1007/s00520-025-09155-9. PMID: 39808329. Observational study. ˍ

Pan J, Shao C, Xu C, Zhang G, Jiang H, Tang T, Tang H, Wu N.
Association between hormone therapy and glioma risk in US women: a cancer screening trial.
Menopause. 2025 Jan 14. doi: 10.1097/GME.0000000000002507. PMID: 39808122. Observational study˰ ˍ

Singh S, Bradford D, Chatterjee S, Li X, Aungst SL, Skinner AM, Miller CP, Kim-McOlash S, Fourie Zirkelbach J, Xiong Y, Bi Y, Wang YH, Yang Y, Sun J, Kraft J, Charlab R, Shord SS, Tang S, Scepura B, Bulatao I, Udoka O, Saber H, Rahman NA, Pazdur R, Singh H, Donoghue M, Drezner N.
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma.
Clin Cancer Res. 2025 Jan 14. doi: 10.1158/1078-0432.CCR-24-3439. PMID: 39808502. Drug updates˰ ˍ

Alan O, Bulbul MC, Enlice MA, Mandel NM.
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.
Immunotherapy. 2025 Jan 15:1-7. doi: 10.1080/1750743X.2025.2451604. PMID: 39812468. Case report˰ ˍ

Sassine S, Ilinca AP, Coltin H, Bittencourt H, Athale U, Bowes L, Brossard J, Israels S, Johnston DL, Kulkarni K, McKillop S, Rayar M, Sinha R, Truong T, Vézina C, Wheaton L, Zorzi AP, Sung L, Pelland-Marcotte MC, Tran TH.
Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada.
Cancer. 2025 Jan 15;131(2):e35673. doi: 10.1002/cncr.35673. PMID: 39801179. Observational study˰ ˍ

Zhong S, Zuo J, Fu X, Wu C, Liu R, Huang Z, Li S.
Leptomeningeal dissemination in H3 K27M- mutant diffuse midline gliomas: clinical characteristics, risk factors, and prognostic insights.
J Neurooncol. 2025 Jan 15. doi: 10.1007/s11060-024-04933-7. PMID: 39812935. Observational study. ˍ

Faison SL, Batonga J, Arumugham T, Bartkus A, Morrison M, Mullin MJ, Tippin T, Naderer O.
A Phase 1 Randomized Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of Dordaviprone and the Effects of Food on the Bioavailability of Dordaviprone in Healthy Adult Subjects.
Clin Pharmacol Drug Dev. 2025 Jan 16. doi: 10.1002/cpdd.1512. PMID: 39817482. Interventional study. ˍ

Sun Y, Wang X, Zhang DY, Zhang Z, Bhattarai JP, Wang Y, Park KH, Dong W, Hung YF, Yang Q, Zhang F, Rajamani K, Mu S, Kennedy BC, Hong Y, Galanaugh J, Sambangi A, Kim SH, Wheeler G, Gonçalves T, Wang Q, Geschwind D, Kawaguchi R, Viaene AN, Helbig I, Kessler SK, Hoke A, Wang H, Xu F, Binder ZA, Chen HI, Pai EL, Stone S, Nasrallah MP, Christian KM, Fuccillo M, Toni N, Wu Z, Cheng HJ, O'Rourke DM, Ma M, Ming GL, Song H.
Brain-wide neuronal circuit connectome of humanglioblastoma.
Nature. 2025 Jan 16. doi: 10.1038/s41586-025-08634-7. PMID: 39821165. Laboratory investigation. ˍ
Update of:
bioRxiv [Preprint]. 2024 Mar 4:2024.03.01.583047. doi: 10.1101/2024.03.01.583047. PMID: 38496540. Laboratory investigation. ˍ

Lee EQ, Alexander BM, Romo CG, Supko JG, Agar NYR, Talebi Z, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Gantchev J, Baquer G, Santagata S, Takebe N, Desideri S, Fisher JD, Sims M, Ye X, Ligon KL, Nabors LB, Grossman SA, Wen PY.
Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
Clin Cancer Res. 2025 Jan 17. doi: 10.1158/1078-0432.CCR-24-2311. PMID: 39820282. Interventional study˰ ˍ

Wills CA, Mohan S, Nabavizadeh A, Patel T, Prior T, Mansour M, McCoy E, Shah S, Angeloni N, O'Neill M, Frangos S, Blessing C, Coghlan L, Maloney E, Wileyto EP, Desai AS, Bagley SJ.
A single-arm phase 2 study of abemaciclib in adult patients with recurrent grade 3 oligodendroglioma.
Neurooncol Adv. 2025 Jan 17;7(1):vdaf011. doi: 10.1093/noajnl/vdaf011. PMID: 39944054. Interventional study. ˍ

Li Y, Wang R, Chen J, Zhu Z, Wang Y, Ma W.
⁶⁸Ga-NOTA-RM26 PET/CT in the evaluation of glioma: a pilot prospective study.
EJNMMI Res. 2025 Jan 17;15(1):6. doi: 10.1186/s13550-025-01198-7. PMID: 39821814. Interventional study. ˍ

Lebeau J, Deprez L, Pintiaux A, Reuter G.
Petroclival meningioma regression after combined oestrogen and nomegestrol acetate interruption.
BMJ Case Rep. 2025 Jan 19;18(1):e263529. doi: 10.1136/bcr-2024-263529. PMID: 39828291. Case report. ˍ

Zhao X, Zhang Y, Wang Y, Ren X, Zhang X, Wan H, Li M, Zhou D.
Prognostic and clinical significance of contrast enhancement in WHO grade 2 oligodendrogliomas.
J Neurooncol. 2025 Jan 19. doi: 10.1007/s11060-024-04929-3. PMID: 39827421. Observational study˰ ˍ